Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Merck Serono spins out newco to develop AD assets

October 3, 2012 12:27 AM UTC

The Merck Serono S.A. division of Merck KGaA (Xetra:MRK) launched Asceneuron (Geneva, Switzerland) to develop the division's preclinical Alzheimer's disease programs targeting microtubule-associated protein-tau (MAPT; TAU, FTDP-17) and beta amyloid. Asceneuron will develop the programs up to Phase I testing and seek a partnership or licensing deal for further development. Merck Serono will invest EUR 5 million ($6.4 million) in seed funding, and Merck Serono Ventures will manage the investment. Asceneuron could not be reached for details. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article